Seelos Therapeutics, Inc. (SEEL): Price and Financial Metrics

Seelos Therapeutics, Inc. (SEEL): $2.35

0.08 (+3.52%)

POWR Rating

Component Grades













Add SEEL to Watchlist
Sign Up

Industry: Biotech


of 509

in industry

SEEL Stock Price Chart Interactive Chart >

Price chart for SEEL

SEEL Price/Volume Stats

Current price $2.35 52-week high $6.60
Prev. close $2.27 52-week low $0.72
Day low $2.21 Volume 6,561,200
Day high $2.37 Avg. volume 5,794,422
50-day MA $2.15 Dividend yield N/A
200-day MA $3.15 Market Cap 240.44M

Seelos Therapeutics, Inc. (SEEL) Company Bio

Seelos Therapeutics, Inc. operates as a biotechnology company. The Company develops treatments for post-traumatic stress and major depressive disorders. Seelos Therapeutics serves patients in the United States.

SEEL Latest News Stream

Event/Time News Detail
Loading, please wait...

SEEL Latest Social Stream

Loading social stream, please wait...

View Full SEEL Social Stream

Latest SEEL News From Around the Web

Below are the latest news stories about Seelos Therapeutics Inc that investors may wish to consider to help them evaluate SEEL as an investment opportunity.

Seelos Therapeutics to Present a Poster on SLS-002 (Intranasal Racemic Ketamine) at the 2021 IASR/AFSP International Summit on Suicide Research

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it has been selected to present a poster on SLS-002 (Intranasal Racemic Ketamine) at the IASR/AFSP International Summit on Suicide Research Virtual Conference, October 24-27th, 2021.

Yahoo | October 1, 2021

Why This Seelos Therapeutics Analyst Is Turning Bullish On Potential Trial Results

Part A results from the trial of Seelos Therapeutics Incs (NASDAQ: SEEL ) intranasal ketamine product candidate, SLS-002, and the

Business Insider Markets | September 27, 2021

Why Seelos Therapeutics Stock Is Trading Higher Today

Seelos Therapeutics Inc (NASDAQ:SEEl) is trading higher Monday after Roth Capital analyst Jonathan Aschoff upgraded the stock from Neutral to Buy and raised the price target from $2.50 to $8. The Roth Capital analyst said the firm's optimism has increased, citing "the stock having found far firmer ground and the transience of the increase in CADSS." Three encouraging features of the ongoing SLS-002 trial came from observing faults with the Spravato trials, Aschoff said: "Requirement for suicidal

Yahoo | September 27, 2021

Is the Options Market Predicting a Spike in Seelos (SEEL) Stock?

Investors need to pay close attention to Seelos (SEEL) stock based on the movements in the options market lately.

Yahoo | September 22, 2021

Seelos Therapeutics Shares Gain On FDA Approval To Add SLS-005 Regimen In HEALEY ALS Trial

The Sean M. Healey & AMG Center for ALS at Mass General received approval from the FDA and the Mass General Brigham Institutional Review Board to add SLS-005 (trehalose injection, 90.5 mg/ML for intravenous infusion) as an additional regimen in the HEALEY ALS Platform Trial. HEALEY ALS Trial Design Committee worked with Seelos Therapeutics Inc (NASDAQ: SEEL) to include SLS-005’s pivotal Phase 2b/3 trial in amyotrophic lateral sclerosis (ALS) on the platform. The drug received Orphan Drug Designa

Yahoo | September 21, 2021

Read More 'SEEL' Stories Here

SEEL Price Returns

1-mo 12.44%
3-mo 1.73%
6-mo -61.85%
1-year 189.30%
3-year -76.33%
5-year -96.80%
YTD 48.73%
2020 17.91%
2019 -76.74%
2018 -89.57%
2017 41.54%
2016 31.31%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.8397 seconds.